Literature DB >> 2165134

Mucosal and systemic antiviral antibodies in mice inoculated intravaginally with herpes simplex virus type 2.

M R McDermott1, L J Brais, M J Evelegh.   

Abstract

Herpes simplex virus type 2 (HSV-2) causes lethal illness after intravaginal (IVAG) inoculation into BALB/cJ mice. In the present studies, we demonstrated in mice that primary IVAG vaccination with an attenuated strain of HSV-2 induced humoral immunity in sera and in vaginal secretions. Secondary genital exposure to HSV-2 enhanced this response. However, intraperitoneal exposure to attenuated HSV-2 elicited an antiviral antibody response in sera but not in vaginal secretions. In both sera and vaginal secretions, antiviral IgG antibodies were the major isotype. Systemic exposure to HSV-2 elicited antibodies only in sera that were specific for the major viral antigens whereas IVAG inoculation with HSV-2 stimulated both serum and vaginal antibody responses. Intravenous transfer of antiviral monoclonal antibodies protected against systemic HSV-2 infection but were ineffective against vaginal infection due to a lack of transudation into vaginal secretions. These results suggested that local humoral immunity in the genital tract is important in resistance to HSV-2.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2165134     DOI: 10.1099/0022-1317-71-7-1497

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  27 in total

1.  Immunoglobulin G is the main protective antibody in mouse vaginal secretions after vaginal immunization with attenuated herpes simplex virus type 2.

Authors:  E L Parr; M B Parr
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

2.  Discovery of potential diagnostic and vaccine antigens in herpes simplex virus 1 and 2 by proteome-wide antibody profiling.

Authors:  Mina Kalantari-Dehaghi; Sookhee Chun; Aziz Alami Chentoufi; Jozelyn Pablo; Li Liang; Gargi Dasgupta; Douglas M Molina; Algis Jasinskas; Rie Nakajima-Sasaki; Jiin Felgner; Gary Hermanson; Lbachir BenMohamed; Philip L Felgner; D Huw Davies
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

3.  Acute and latent infection of mice immunised with HSV-1 ISCOM vaccine.

Authors:  M Erturk; T J Hill; C Shimeld; R Jennings
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

4.  Immunization of the female genital tract with a DNA-based vaccine.

Authors:  J B Livingston; S Lu; H Robinson; D J Anderson
Journal:  Infect Immun       Date:  1998-01       Impact factor: 3.441

5.  Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells.

Authors:  L A Morrison; L Zhu; L G Thebeau
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

6.  Immunoglobulin G, plasma cells, and lymphocytes in the murine vagina after vaginal or parenteral immunization with attenuated herpes simplex virus type 2.

Authors:  E L Parr; M B Parr
Journal:  J Virol       Date:  1998-06       Impact factor: 5.103

7.  Transfer of IgG in the female genital tract by MHC class I-related neonatal Fc receptor (FcRn) confers protective immunity to vaginal infection.

Authors:  Zili Li; Senthilkumar Palaniyandi; Rongyu Zeng; Wenbin Tuo; Derry C Roopenian; Xiaoping Zhu
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-28       Impact factor: 11.205

8.  Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection.

Authors:  Richard B Pyles; Debbie Higgins; Claudia Chalk; Anthony Zalar; Joseph Eiden; Carrie Brown; Gary Van Nest; Lawrence R Stanberry
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

9.  Cervicovaginal neutralizing antibodies to herpes simplex virus (HSV) in women seropositive for HSV Types 1 and 2.

Authors:  Francois-Xavier Mbopi-Kéou; Laurent Bélec; Julie Dalessio; Jérôme Legoff; Gérard Grésenguet; Philippe Mayaud; David W G Brown; Rhoda Ashley Morrow
Journal:  Clin Diagn Lab Immunol       Date:  2003-05

10.  Mucosal innate and adaptive immune responses against herpes simplex virus type 2 in a humanized mouse model.

Authors:  Amanda Kwant-Mitchell; Ali A Ashkar; Kenneth L Rosenthal
Journal:  J Virol       Date:  2009-08-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.